Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
This research is an extension study for a medicine called sevasemten, which is being investigated for Becker muscular dystrophy. The main goal is to find out if taking sevasemten for a longer time is safe and if it continues to help people with their symptoms. Scientists will be checking different things like safety, how the body reacts to the medicine (biomarkers), and if it improves how people function day-to-day. This study is specifically for men who have already taken part in previous research trials involving sevasemten. It gives them the chance to continue receiving the treatment and helps researchers understand its long-term benefits and any potential downsides.
At a glance
What is this study about?
This study is called MESA, and it's looking at a medicine named sevasemten, also known as EDG-5506, for people who have Becker muscular dystrophy. It's an 'open-label extension' study, which means that everyone taking part will know they are receiving the actual medicine, not a dummy treatment (placebo), and it builds on earlier studies. The main idea is to see what happens when people take sevasemten over a much longer period.
The researchers want to understand two key things: first, is it safe to take sevasemten for a long time? And second, does it continue to help with Becker muscular dystrophy over many months or even years? They'll be carefully checking for any side effects and also looking at signs in the body that show how the medicine is working. They'll also assess if people's daily activities and physical abilities improve or stay stable.
This study is really important because it could give us a better picture of the long-term effects of sevasemten. Knowing how a medicine works and if it's safe over a long time is crucial for deciding if it can become a regular treatment for Becker muscular dystrophy. It helps ensure that any potential benefits outweigh the risks for those living with the condition.
Key takeaways
- This study is for men with Becker muscular dystrophy who have already taken part in specific prior studies of sevasemten.
- It aims to understand the long-term safety and effects of sevasemten over a longer period.
- Participants will continue to receive sevasemten and be closely monitored by doctors.
- The study helps researchers learn more about how this investigational medicine works over time.
- Participation is voluntary, and you can leave the study at any point.
Who may be eligible?
To be able to join this study, you must be a male who has been diagnosed with Becker muscular dystrophy. You also need to have successfully completed one of the previous studies involving the same medicine, sevasemten. These previous studies are known as EDG-5506-002 ARCH, EDG-5506-201 CANYON and GRAND CANYON, or EDG-5506-202 DUNE. You'll need to have finished all the required visits for your particular previous study.
There are some reasons why you might not be able to join. For example, if your health has changed significantly since your last study in a way that the doctors think would make taking sevasemten unsafe for you. Also, if you are taking certain other medications that could interfere with sevasemten, you wouldn't be able to join. This includes medicines that strongly affect how the body processes other drugs.
Finally, if you've been part of another research study testing a different medicine within the last 30 days (or longer, depending on the other medicine), you wouldn't be able to join this one right away. Also, if you've taken steroid medicines for your Becker muscular dystrophy in the last six months, you would not be eligible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you male and have Becker muscular dystrophy?
- Have you already completed all visits for the EDG-5506-002 ARCH, EDG-5506-201 CANYON and GRAND CANYON, or EDG-5506-202 DUNE study?
- Do you avoid taking certain strong medications that might react with sevasemten?
- Have you avoided other experimental drugs within the last month and oral steroids for BMD in the last 6 months?
- Has your health remained stable since your last study, without new significant issues?
What does participation involve?
If you join this study, you will continue to receive the study medicine, sevasemten. Since this is an extension study, the exact details of visits and checks will likely follow a similar pattern to the previous studies you've been part of, but over a longer time. You'll have regular appointments at a clinic where doctors and nurses will monitor your health, check for any side effects, and assess how the medicine is working. This will involve physical examinations, blood tests, and possibly other tests to measure your physical abilities and disease progression. You'll be taking the study medicine regularly as instructed. The total duration of your participation will depend on the study design, but it's set up for long-term follow-up to see the impact of continued treatment.
Potential risks and benefits
Locations (46)
- Arkansas Children's HospitalVerified postcodeLittle Rock, United States
- UC San DiegoVerified postcodeLa Jolla, United States
- UCLA Medical CenterVerified postcodeLos Angeles, United States
- UC Irvine Medical CenterVerified postcodeOrange, United States
- Stanford Neuroscience Health CenterVerified postcodePalo Alto, United States
- UC Davis Medical CenterVerified postcodeSacramento, United States
- UC DenverVerified postcodeAurora, United States
- University of FloridaVerified postcodeGainesville, United States
- Rare Disease ResearchVerified postcodeAtlanta, United States
- Northwestern UniversityVerified postcodeChicago, United States
- Indiana University School of MedicineVerified postcodeIndianapolis, United States
- University of IowaVerified postcodeIowa City, United States
Common questions
What is Becker muscular dystrophy?
Becker muscular dystrophy is a genetic condition that causes muscles to become weak and waste away over time. It mainly affects boys and men.
What is sevasemten (EDG-5506)?
Sevasemten is a medicine being tested to see if it can help people with Becker muscular dystrophy. It's not yet a widely approved treatment.
Why is this an 'extension' study?
It's an extension study because it gives people who were in earlier trials for sevasemten the chance to keep taking the medicine and allows researchers to learn about its long-term effects.
Will I know if I'm getting the real medicine?
Yes, this is an 'open-label' study, which means everyone involved knows that participants are receiving the active medicine, sevasemten.
How long would I need to be in the study?
The study aims to look at the long-term effects, so participation is expected to be for an extended period, which builds on the time you've already spent in previous studies.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.